Articles tagged with Pancreatic Tumors
A team of researchers identified a process that promotes the growth of pancreatic cancers and developed a method to disrupt it. By inhibiting adhesion molecule CDH11, they were able to reduce tumor growth, increase the effectiveness of chemotherapy, and extend mouse survival.
Researchers at Memorial Sloan Kettering Cancer Center found that tumors with high mutation burden, particularly those with BRCA2 mutations, respond better to immunotherapy. This discovery may lead to more precise treatments for patients with BRCA2 mutations.
The new WEHI-TV animation explains how the 'tumour suppressor' protein p53 prevents cancer-causing changes in cells. More than half of human cancers involve faulty p53, and researchers are still working to develop better therapies for these cancers.
Researchers have developed a novel antibody-drug conjugate that selectively recognizes and penetrates pancreatic tumors, reducing tumor size and metastasis. The treatment, which uses MRI-based molecular imaging to monitor its effect, shows promise as a more precise approach than existing treatments.
Researchers found that high concentrations of sunitinib in tumors, but not blood plasma, are associated with improved patient outcomes. The study's results suggest a safer and more effective treatment strategy for patients with advanced cancers.
Researchers define two molecular subtypes of pancreatic carcinoma with distinct aggressiveness, differing in the origin and development. The study reveals a novel mechanism called viral mimicry that promotes cancer growth and metastasis.
The study investigates the cooperative effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice. The authors demonstrate that pRB has the strongest cooperative function with PTEN in suppressing Pit NETs and Menin and TRP53 in suppressing Pan NETs.
Researchers developed a new nanoscale metal-organic framework design to deliver targeted, personalized vaccines for cancer treatment. The approach leverages radiation treatment and the adaptive immune response to kill cancer cells directly and trigger an immune response against tumor cells.
Researchers have developed a mouse model of pancreatic cancer that replicates two subtypes of the disease, classifying them as classical PDAC and basal PDAC. The study reveals key genes driving the aggressive nature of basal PDAC, offering potential targets for therapy.
A Phase II trial led by MD Anderson Cancer Center researchers found that treatment with MK-6482 resulted in a 27.9% objective response rate in patients with von Hippel-Lindau disease-associated renal cell carcinoma, with most side effects being grade 1 or 2. The drug directly targets HIF-2a and has been shown to be well-tolerated.
This review article discusses the features of challenging cold tumors and potential approaches to transform them into hot tumors, which are more responsive to immunotherapy. The authors summarize current strategies for enhancing T cell trafficking and discuss the limitations of existing immunotherapeutic approaches.
Researchers have developed a unique immunotherapy delivery system that can turn cold tumors into 'hot' tumors, making it effective in cancers such as breast and melanoma. The system uses a protein called interleukin 12 to inflame the tumor and activate the immune system.
Researchers developed a new concept of resectability and identified objective pre-operative prognostic factors to predict long-term survival in pancreatic cancer patients. The study's nomogram can estimate patient outcomes before surgery, regardless of local anatomic features.
Researchers in Brazil identified a gene expression profile associated with cachexia, a potentially fatal syndrome characterized by severe weight loss and muscle wasting. The study found that pancreatic, esophageal, colorectal, stomach, and head-and-neck cancers are most frequently linked to cachexia.
Results from 46 patients who received targeted therapies alongside standard chemotherapy showed a 31-month average survival compared to 18 months for those without molecular changes. Targeted therapy has already improved survival for many forms of cancer and could be a game-changer for pancreatic cancer patients with specific alterations.
Researchers have found a promising candidate to advance pancreatic cancer immunotherapy: innate lymphoid cells (ILCs), particularly ILC2s. Activating ILC2s with interleukin 33 (IL-33) enhances antitumor activity, which may complement existing checkpoint inhibitors.
Researchers developed a pancreatic tumor model that condenses cancer development to just two weeks, allowing them to observe trends in cell growth and invasion. The study found that cancer cells from different mutations become more invasive when they grow together, which challenges the current understanding of disease progression.
NETRF has funded $3.5 million in neuroendocrine tumor research grants to advance treatment options. The grants support innovative approaches to immunotherapy, pheochromocytoma and paraganglioma research, and lung NET studies.
Researchers developed a novel anti-CEACAM antibody for fluorescence visualization of colorectal tumors and metastases. The antibody targets multiple CEACAMs, which can lead to improved detection of tumor margins and metastases with variable expression of CEA.
Researchers found that pancreatic tumor cells secrete interleukin-1β (IL-1β) to reduce anti-cancer immune responses, promoting PDA tumor growth. Blocking IL-1β with an antibody treatment doubled T cell infiltration and increased PD-1 blockade efficacy by 40%.
Pancreatic cancer cells use a process called macropinocytosis to engulf nutrients, which are then broken down into building blocks for cell growth. The study identified key molecular steps involved in boosting this process, including the activation of protein kinase A and v-ATPase.
Researchers at Fred Hutchinson Cancer Center have successfully shrunk solid tumors using a thin metal mesh loaded with CAR T cells in preclinical models of ovarian cancer. The approach showed promising results, clearing tumors in 70% of treated mice within 20 days.
Researchers developed a new two-subtype system to classify pancreatic cancer tumors based on treatment response data from clinical trials. The study found that patients with basal-like tumors showed poor responses to common therapies and worse survival outcomes.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice, supporting the immediate evaluation of the drugs in a clinical trial. The study provides rationale for an immediate clinical trial evaluating the 2 therapies
Researchers have discovered that mitochondria undergo reprogramming under low oxygen conditions, a process that could provide new therapeutic targets for pancreatic cancer. This reprogramming enables cancer cells to adapt to energy scarcity by switching to glycolysis, allowing them to continue growing despite limited nutrients and oxygen.
A non-invasive imaging technique can assess tumor stiffness, providing valuable diagnostic information about breast and pancreatic tumors. The technique, magnetic resonance elastography, may help select the best treatment course for some cancer patients.
Research reveals that hypoxic conditions alter p53's shape, allowing it to bind with HIF and promote cancer cell survival. This discovery may lead to new therapeutic strategies for pancreatic cancer.
Researchers at UC San Diego have developed a new therapeutic approach to convert tumor-associated macrophages (TAMs) into cancer killers. The antibody, LM609, induces ADCC and kills drug-resistant tumors, prolonging response to standard treatments.
Researchers found that pancreatic tumours produce more perlecan to remodel the environment, helping cancer cells spread and resist chemotherapy. Lowering perlecan levels improved response to treatment in mouse models.
Long-term survivors of pancreatic cancer have a diverse tumor microbiome, which boosts their immune attack on tumors. Fecal transplant treatments can alter the tumor microbiome, suggesting a potential therapeutic opportunity for improving pancreatic cancer treatment.
Researchers developed a nonwoven fabric bioabsorbable spacer that creates a space between healthy and cancerous tissues during particle therapy, preserving distance between tumors and normal organs. The spacer safely absorbs by the body without causing serious complications.
Researchers have identified a key protein involved in pancreatic cancer cell growth and found an antibody therapy that targets it, reducing tumour growth and increasing survival time in mice. The treatment combines the antibody with gemcitabine and achieves up to a sixfold increase in survival time compared to controls.
Scientists identified two subtypes of pNETs, type A (ARX-expressing) and type B (PDX1-expressing), with dramatically different risks of recurrence following surgical treatment. Type B tumors have an excellent prognosis, while type A tumors require vigilant monitoring for potential recurrence.
Researchers discover a novel compound that activates CD11b receptors on white blood cells, promoting an anti-tumor immune response and overcoming resistance to immunotherapies. This breakthrough may lead to new treatments for the third deadliest cancer in the US.
Researchers have identified a signaling pathway regulating macropinocytosis in pancreatic tumors, which could lead to personalized treatments. The study reveals that tumors can dynamically adjust their nutrient uptake, with some 'dialing up' or 'dialing down' macropinocytosis based on glutamine availability.
A novel radiotracer has been identified that can detect nearly 30 types of cancer using positron emission tomography/computed tomography (PET/CT). This technology shows promise for new applications in noninvasive diagnosis, staging and treatment.
A novel protocol combining intensive chemotherapy, radiation therapy and blood-pressure drug losartan has allowed complete removal of tumors in 61% of participants with locally advanced pancreatic cancer. The treatment significantly improved survival rates and was found to activate immune system pathways.
New research finds elevated levels of fatty acid transporter protein 2 (FATP2) in immune-suppressing cells, which can slow tumor growth and aid cancer treatments. The study also discovered an energy-granting lipid that FATP2 produces and traffics into cells, leading to its potential as a therapeutic target.
Researchers found that the nutrient composition of interstitial fluid surrounding pancreatic tumors differs from blood and culture medium used to grow cancer cells. This discrepancy suggests growing cancer cells in a more similar environment could help predict how experimental drugs will affect cancer cells.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
Researchers have developed a mini-protein MYC inhibitor that effectively treats non-small cell lung cancer, exhibiting minimal side effects. The therapy works by targeting the MYC oncogene, leading to reduced tumor growth and improved patient outcomes.
A recent study reports radiation contamination at an Arizona crematorium following treatment of a patient with a radioactive drug. The contamination was detected on equipment and in the operator's urine, raising concerns about potential health effects.
Researchers at The Wistar Institute have discovered a novel role of NAD+ metabolism in promoting tumor growth and progression in preclinical models of pancreatic cancer. Cellular senescence, a process that stops cells from dividing, can also produce proinflammatory molecules that promote tumor growth.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $2.5 million in grants to support research into neuroendocrine cancers, including lung NETs. These grants will fund projects exploring various innovative therapies, such as CAR T-cell therapy and photodynamic therapy.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
Researchers identified VISTA on immune cells infiltrating pancreatic tumors, which resisted immune checkpoint blockade drugs. The study highlights the importance of stroma and found higher expression of VISTA in pancreatic tumors compared to melanoma.
A Columbia professor has developed a predictive computer platform that analyzes all tumor types and predicts effective treatment options. The platform, OncoTreat, is based on advanced data science techniques, including information theory and ray-tracing.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
Researchers have developed a new method that can detect hard-to-trace tumor DNA in the blood by focusing on specific fragment sizes. The technique improves cancer detection and may also be applicable to other types of DNA in body fluids.
Researchers at Cold Spring Harbor Laboratory have identified molecular signals that can convert tumor-promoting fibroblasts into beneficial ones in pancreatic tumors. By manipulating these signals, they aim to recruit tumor-restricting cells into the anticancer fight and develop a combination therapy approach.
Researchers developed an antibody to block DKK3, which stimulated cancer growth and resistance to therapy. In a mouse study, the treatment significantly prolonged life and boosted immune cell infiltration.
Researchers at UNIGE and HUG discovered that mucinous tumours of the ovary and pancreas originate from embryonic germ cells that migrate to reproductive organs. These cells can mistakenly stop in other organs, leading to cancer decades later.
A new imaging method targets cancer-associated fibroblasts to diagnose widespread tumors like breast, colon, and pancreas cancer with better accuracy and less inconvenience. The tracer shows high tumor uptake and image contrast, making it a promising strategy for detection and treatment of malignant tumors.
Researchers have developed a new method using TOF-SIMS to map the flow of biomolecules in and around solid tumors. This technique reveals how tumors signal to their microenvironment and sap local tissue resources.
A Penn Medicine team discovered that tumor heterogeneity, regulated by genes specific to each tumor, determines whether a tumor is hot or cold. This understanding could help oncologists tailor treatments to a patient's unique tumor composition.
Researchers have developed a new nuclear medicine procedure that can safely and effectively detect cancerous gastrointestinal and pancreatic neuroendocrine tumors. The novel radiolabeled tracer Ga-OPS202 has been shown to improve imaging contrast and sensitivity for detecting primary tumors or liver metastases.
Researchers created a pioneering 3D cancer model to replicate complex tumor behavior and accelerate treatment development. The model can mimic patients' tumors, allowing doctors to identify the best treatment option based on simple biopsies.
A study published in the Genes & Development journal reveals that tumor cells can survive even without Ras genes if Erf is also lost, casting doubt on the effectiveness of potential treatments. The researchers found that eliminating ERF allows mouse stem cells to grow and differentiate in the absence of RAS genes.
Researchers at UT Health San Antonio have created a novel technology that injects a modified virus into the mouse pancreas with pro-cancer molecules, resulting in human-like tumors. This breakthrough could lead to new insights into pancreatic cancer initiation and progression, as well as spur new drug development.
A new clinical trial combines two immunotherapies, PD-1 antibody and poly-IC, to enhance T-cell response against solid tumors. The treatment aims to improve patient outcomes for a wide range of cancers, including lung, liver, colon, and others.